Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EMMAUS LIFE SCIENCES, INC.NONE · Entity 156030 | Director · Chairman and CEO · 10% owner | July 09, 2019 | July 11, 2019 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director · Chairman and CEO · 10% owner | January 12, 2023 | January 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EMMAUS LIFE SCIENCES, INC.
Report date July 09, 2019 · Filed July 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Promissory Note dated 9/14/17, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | Direct | 1 |
Reported balance
After 2019-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. |
| Promissory Note dated 3/6/16, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | IndirectBy Hope International Hospice, Inc. | 1 |
Reported balance
After 2019-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown. |
Filing footnotes · ownership attribution and instrument terms
F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc.
F2: See footnote 1.
F3: Represents the outside date for completion of the proposed merger, unless extended by the parties.
F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction.
F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown.
Emmaus Life Sciences, Inc.
Report date January 12, 2023 · Filed January 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2028-01-11 | Direct | 0 |
Reported balance
After 2023-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-12 · Grant · Acquired 7,500,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2020 Filed Jun 23, 2020 17:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,200 | $1.74 | $2,088.00 |
DisclosureSEC source: 0001209191-20-038401 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,673,393 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.73 to $1.75, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 16:20 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.67 | $1,670.00 |
DisclosureSEC source: 0001209191-20-037529 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,672,193 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.67, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 17:37 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $1.67 | $835.00 |
DisclosureSEC source: 0001209191-20-036922 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,671,193 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.66 to $1.69, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 17:37 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.67 | $1,670.00 |
DisclosureSEC source: 0001209191-20-036922 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,670,693 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.69, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:16 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,800 | $1.75 | $8,400.00 |
DisclosureSEC source: 0001209191-20-036254 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,669,693 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.78, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:16 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.78 | $2,670.00 |
DisclosureSEC source: 0001209191-20-036254 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,664,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.78 to $1.79, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 17:52 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,500 | $1.71 | $5,985.00 |
DisclosureSEC source: 0001209191-20-035475 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,663,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.78, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 17:52 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,700 | $1.69 | $4,563.00 |
DisclosureSEC source: 0001209191-20-035475 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,659,893 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.60 to $1.75, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 19:50 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,200 | $1.61 | $5,152.00 |
DisclosureSEC source: 0001209191-20-034946 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,657,193 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 19:50 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,500 | $1.59 | $3,975.00 |
DisclosureSEC source: 0001209191-20-034946 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,653,993 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.60, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 17:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $1.52 | $6,080.00 |
DisclosureSEC source: 0001209191-20-034376 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,651,493 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.49 to $1.59, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 17:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.60 | $3,200.00 |
DisclosureSEC source: 0001209191-20-034376 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,647,493 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.65, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 18:14 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,500 | $1.60 | $4,000.00 |
DisclosureSEC source: 0001209191-20-033404 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,645,493 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.62, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:14 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,200 | $1.51 | $4,832.00 |
DisclosureSEC source: 0001209191-20-033404 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,642,993 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.42 to $1.58, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 28, 2020 Filed May 29, 2020 17:54 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,200 | $1.37 | $3,014.00 |
DisclosureSEC source: 0001209191-20-032863 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,639,793 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.39, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 27, 2020 Filed May 29, 2020 17:54 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $1.35 | $675.00 |
DisclosureSEC source: 0001209191-20-032863 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,637,593 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 26, 2020 Filed May 27, 2020 17:54 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 600 | $1.37 | $822.00 |
DisclosureSEC source: 0001209191-20-032256 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,637,093 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 22, 2020 Filed May 27, 2020 17:54 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.38 | $1,380.00 |
DisclosureSEC source: 0001209191-20-032256 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,636,493 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.37 to $1.38, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 21, 2020 Filed May 22, 2020 17:30 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,700 | $1.37 | $2,329.00 |
DisclosureSEC source: 0001209191-20-031637 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,635,493 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.39, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 20, 2020 Filed May 22, 2020 17:30 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $1.40 | $5,600.00 |
DisclosureSEC source: 0001209191-20-031637 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,633,793 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 18, 2020 Filed May 20, 2020 19:52 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $1.35 | $675.00 |
DisclosureSEC source: 0001209191-20-030845 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,629,793 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:21 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $1.29 | $645.00 |
DisclosureSEC source: 0001209191-20-030174 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,629,293 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.30, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 14, 2020 Filed May 18, 2020 21:21 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,400 | $1.29 | $1,806.00 |
DisclosureSEC source: 0001209191-20-030174 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,628,793 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.30, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 13, 2020 Filed May 14, 2020 19:24 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,100 | $1.26 | $2,646.00 |
DisclosureSEC source: 0001209191-20-029121 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,627,393 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.25 to $1.28, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 12, 2020 Filed May 14, 2020 19:24 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,200 | $1.32 | $4,224.00 |
DisclosureSEC source: 0001209191-20-029121 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625,293 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.26 to $1.35, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 08, 2020 Filed May 11, 2020 22:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,900 | $1.27 | $6,223.00 |
DisclosureSEC source: 0001209191-20-028377 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,622,093 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 07, 2020 Filed May 11, 2020 22:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,950 | $1.25 | $3,687.50 |
DisclosureSEC source: 0001209191-20-028377 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,617,193 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.28, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 06, 2020 Filed May 7, 2020 22:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.30 | $1,300.00 |
DisclosureSEC source: 0001209191-20-027783 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,614,243 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,000 | $1.32 | $3,960.00 |
DisclosureSEC source: 0001209191-20-027783 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,613,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.29 to $1.33, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 04, 2020 Filed May 5, 2020 23:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,000 | $1.28 | $3,840.00 |
DisclosureSEC source: 0001209191-20-027305 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,610,243 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.31, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| May 01, 2020 Filed May 5, 2020 23:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $1.21 | $6,050.00 |
DisclosureSEC source: 0001209191-20-027305 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,607,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.29, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 18:36 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 14,000 | $1.75 | $24,500.00 |
DisclosureSEC source: 0001209191-20-024466 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,602,243 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.88, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 18:36 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,300 | $1.37 | $4,521.00 |
DisclosureSEC source: 0001209191-20-024466 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,588,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.30 to $1.40, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 09, 2020 Filed Apr 10, 2020 18:05 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,700 | $1.28 | $8,576.00 |
DisclosureSEC source: 0001209191-20-024118 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,584,943 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.19 to $1.39, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 18:05 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,200 | $1.30 | $4,160.00 |
DisclosureSEC source: 0001209191-20-024118 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,578,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.38, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 00:06 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,100 | $1.25 | $2,625.00 |
DisclosureSEC source: 0001209191-20-023886 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575,043 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.25, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 00:06 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,700 | $1.26 | $5,922.00 |
DisclosureSEC source: 0001209191-20-023886 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,572,943 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.30, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 03, 2020 Filed Apr 8, 2020 00:06 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,200 | $1.24 | $7,688.00 |
DisclosureSEC source: 0001209191-20-023886 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,568,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.25, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 18:43 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 8,300 | $1.23 | $10,209.00 |
DisclosureSEC source: 0001209191-20-023033 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,562,043 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.15 to $1.25, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 18:43 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 22,500 | $1.27 | $28,575.00 |
DisclosureSEC source: 0001209191-20-023033 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,553,743 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.16 to $1.33, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 31, 2020 Filed Apr 3, 2020 01:00 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 13,200 | $1.21 | $15,972.00 |
DisclosureSEC source: 0001209191-20-022897 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,531,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.32, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 30, 2020 Filed Mar 30, 2020 22:21 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.29 | $1,935.00 |
DisclosureSEC source: 0001209191-20-021746 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,518,043 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.34, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 22:21 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,500 | $1.21 | $4,235.00 |
DisclosureSEC source: 0001209191-20-021746 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516,543 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.24, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 22:21 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 14,200 | $1.07 | $15,194.00 |
DisclosureSEC source: 0001209191-20-021746 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,513,043 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.95 to $1.20, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 23:57 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,900 | $1.48 | $7,252.00 |
DisclosureSEC source: 0001209191-20-020771 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,498,843 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.65, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 18, 2020 Filed Mar 18, 2020 23:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,000 | $1.46 | $4,380.00 |
DisclosureSEC source: 0001209191-20-020105 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,493,943 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.65, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 23:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,700 | $1.61 | $4,347.00 |
DisclosureSEC source: 0001209191-20-020105 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490,943 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.64, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 23:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.58 | $2,370.00 |
DisclosureSEC source: 0001209191-20-020105 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,488,243 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.56 to $1.62, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 13, 2020 Filed Mar 13, 2020 22:37 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,100 | $1.61 | $9,821.00 |
DisclosureSEC source: 0001209191-20-019028 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,486,743 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.75, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 22:37 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,000 | $1.55 | $4,650.00 |
DisclosureSEC source: 0001209191-20-019028 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,480,643 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.63, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.